Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Moderna, Inc. - Common Stock (NQ:MRNA)

26.77 -1.14 (-4.08%)
Streaming Delayed Price Updated: 10:51 AM EDT, Aug 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Moderna, Inc. - Common Stock

If You're in Your 30s, Consider Buying These 2 Healthcare Stocks
Both companies have helped pioneer important medical breakthroughs. 
Via The Motley Fool
Topics Government Intellectual Property Retirement
UnitedHealth's Best Day Since 2008, Intel's Best Weekly Gain In Decades: What's Moving Markets Friday?
Major tech-heavy indices edged lower from record highs by midday Friday in New York, as investors adopted a cautious stance ahead of the Trump-Putin meeting and after data showed a dip in consumer... 
Via Benzinga
Topics Economy
Explore the top gainers and losers within the S&P500 index in today's session.
Curious about the top performers within the S&P500 index in the middle of the day on Friday? Dive into the list of today's session's top gainers and losers for a comprehensive overview. 
Via Chartmill
Biogen, Moderna, Align Technology, QuidelOrtho, and Masimo Shares Skyrocket, What You Need To Know
A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer... 
Via StockStory
Topics Economy
Exploring the top movers within the S&P500 index during today's session.
Curious about the top performers within the S&P500 index in the middle of the day on Wednesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview. 
Via Chartmill
MRNA Q2 Deep Dive: Revenue Beat Overshadowed by Lower Guidance and Cost Cuts
Biotechnology company Moderna (NASDAQ:MRNA) announced better-than-expected revenue in Q2 CY2025, but sales fell by 41.1% year on year to $142 million. On the other hand, the company’s full-year revenue... 
Via StockStory
Moderna, Teleflex, Envista, Enovis, and UnitedHealth Shares Are Soaring, What You Need To Know
A number of stocks jumped in the morning session after positive inflation data fueled hopes for an interest rate cut by the Federal Reserve. The latest Consumer Price Index (CPI) report showed... 
Via StockStory
Topics Bonds Economy Stocks
CDC Shooting Linked To Suspect's COVID-19 Vaccine Beliefs, Former Staff Blame RFK Jr. Hostility Toward Agency
CDC shooting tied to anti-vaccine beliefs sparks warnings from staff, as leaders clash over the future of mRNA vaccines and federal health policy. 
Via Benzinga
What's Driving the Market Sentiment Around Moderna?
 
Via Benzinga
Pfizer In Spotlight As FDA Reportedly Mulls Withdrawing Authorization For COVID-19 Vaccine For Kids Under 5: Retail Says Stock Is Undervalued
According to a Bloomberg report, Pfizer has requested that the approval stay in place through the coming fall season. 
Via Stocktwits
FDA May Not Renew Pfizer's Authorization For Covid Shots In Younger Children, Moderna Prepares To Boost Supply
Pfizer's COVID-19 vaccine for children under five may lose FDA authorization, leading to potential supply shortages. Modern on board to fill in gaps. 
Via Benzinga
Vinay Prasad's Comeback To FDA Sparks Debate Over Regulatory Direction
Vinay Prasad returns as FDA's CBER director after brief exit, raising questions on rare disease drug approvals and mRNA vaccine oversight. 
Via Benzinga
The 3 Things That Matter for Moderna Now
The company is still trying to prove that it isn't just a pandemic play. 
Via The Motley Fool
3 Cash-Burning Stocks That Fall Short
Rapid spending isn’t always a sign of progress. Some cash-burning businesses fail to convert investments into meaningful competitive advantages, leaving them vulnerable. 
Via StockStory
RFK Jr. Halts $500 Million In mRNA Vaccine Projects Backed By Pfizer, Moderna: 'We're Prioritizing Safer, Broader Strategies'
The Department of Health and Human Services will cancel 22 vaccine development projects totaling $500 million. 
Via Benzinga
1 S&P 500 Stock to Consider Right Now and 2 Facing Headwinds
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth,... 
Via StockStory
Topics Stocks
Moderna, Pfizer, Sanofi In Focus As US Winds Down mRNA Vaccine Plans; Retail Turns Bearish On AstraZeneca
Via Stocktwits
Novo Nordisk, United Parcel Service, And Moderna Are Among Top 10 Large Cap Losers Last Week (July 28-August 1): Are The Others In Your Portfolio?
Ten large-cap stocks, including Novo Nordisk and UPS, tumbled last week on weak earnings and guidance cuts. 
Via Benzinga
Discover which S&P500 stocks are making waves on Friday.
Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Friday as we examine the latest happenings in today's session. 
Via Chartmill
Stay informed with the top movers within the S&P500 index on Friday.
Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Friday as we examine the latest happenings in today's session. 
Via Chartmill
Why Moderna (MRNA) Stock Is Trading Lower Today
Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 7.1% in the afternoon session after the company trimmed the upper end of its 2025 revenue forecast, citing a delay in vaccine shipments. The... 
Via StockStory
Novavax Stock Dips As Moderna's Woes Weigh On Vaccine Sector
Shares of Novavax are trading lower Friday morning. The stock appears to be caught in a downdraft affecting COVID-19 vaccine makers after rival Moderna reported disappointing Q2 results. 
Via Benzinga
Which S&P500 stocks are gapping on Friday?
Curious about the market action on Friday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session. 
Via Chartmill
Moderna CEO Attributes Full-Year Revenue Guidance Reduction To Timing Of Shipments: Retail Pins Hopes On Pipeline After Q2 Beat
The vaccine maker lowered its full-year revenue guidance to a range of $1.5 billion to $2.2 billion, reflecting a $300 million reduction at the high end of the range. 
Via Stocktwits
Topics Artificial Intelligence
Moderna's Key Patent Win Overshadowed By Gloomy Outlook
Moderna beat Q2 earnings and revenue estimates, narrowed its annual forecast, won a key patent case, and plans to cut 10% of its global workforce. 
Via Benzinga
Topics Intellectual Property
Top S&P500 movers in Friday's pre-market session
Curious about the S&P500 stocks that are showing activity before the opening bell on Friday? 
Via Chartmill
Moderna (NASDAQ:MRNA) Exceeds Q2 Expectations But Stock Drops
Biotechnology company Moderna (NASDAQ:MRNA) reported Q2 CY2025 results exceeding the market’s revenue expectations, but sales fell by 41.1% year on year to $142 million. On the other hand, the... 
Via StockStory
Moderna Stock Falls Again Amid Lowered Guidance, Job Cuts
The biotech reported a smaller-than-expected Q2 loss and revenue decline. 
Via Investor's Business Daily
Topics Artificial Intelligence
Dow Futures Decline As Trump Unleashes Tariffs Globally: AAPL, AMZN, COIN, RDDT, CVX, XOM Among Stocks To Watch
While Dow Jones futures were down 0.94% at the time of writing, the S&P 500 futures fell 0.95%. 
Via Stocktwits
Topics ETFs Government Stocks
Moderna Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
 
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.